• If you are wondering whether Amneal Pharmaceuticals' current share price reflects its true worth, the recent returns give you plenty to think about.
• The stock last closed at US$12.80, with a 2.6% return over 7 days, a 4.1% decline over 30 days, a 1.1% return year to date, and a very strong 83.6% return over the past year, alongside a very large gain over 3 years and a 116.9% return over 5 years.
• Recent price moves have put more attention on how Amneal Pharmaceuticals is being valued and what is driving sentiment. While short term swings can reflect changing views on risk, longer term performance often pushes investors to question whether the current market price still lines up with fundamentals.
• On Simply Wall St's valuation checks, Amneal Pharmaceuticals currently has a valuation score of 3 out of 6. The next sections will break down what different valuation methods say about the stock and then finish with a broader way to think about value beyond a single metric.

Approach 1: Amneal Pharmaceuticals Discounted Cash Flow (DCF) Analysis

A Discounted Cash Flow (DCF) model looks at the cash Amneal Pharmaceuticals may generate in the future, then discounts those cash flows back to today to estimate what the business could be worth right now.

Amneal’s latest twelve month Free Cash Flow (FCF) is around $244.9 million. The DCF model used here is a 2 Stage Free Cash Flow to Equity approach, which incorporates analyst inputs and then extends them. For example, Simply Wall St uses analyst projections such as $333.4 million FCF in 2026 and $342.9 million in 2027, then extrapolates further out, with FCF of $555.0 million in 2028 and continuing projections through 2035.

On this basis, the model arrives at an estimated intrinsic value of about $65.67 per share. Compared with the recent share price of US$12.80, this implies an intrinsic discount of roughly 80.5%, which points to the shares trading at a substantial markdown relative to this cash flow based estimate.

Result: UNDERVALUED

Our Discounted Cash Flow (DCF) analysis suggests Amneal Pharmaceuticals is undervalued by 80.5%. Track this in your watchlist or portfolio, or discover 62 more high quality undervalued stocks.

Approach 2: Amneal Pharmaceuticals Price vs Earnings

For profitable companies, the P/E ratio is a useful way to judge how much you are paying for each dollar of earnings. It ties the share price directly to the business’s current earnings power, which many investors use as a quick anchor for value.

What counts as a “normal” P/E depends on how the market views a company’s growth prospects and risk. Higher expected growth and lower perceived risk usually support a higher P/E, while slower growth or higher risk tend to justify a lower one.

Amneal Pharmaceuticals currently trades on a P/E of 56.67x. That is above both the Pharmaceuticals industry average of 16.88x and the peer average of 30.93x. Simply Wall St also calculates a proprietary “Fair Ratio” of 18.57x. This is the P/E level suggested by factors such as Amneal’s earnings growth profile, profit margins, industry, market cap and specific risks.

This Fair Ratio aims to be more tailored than a simple comparison with peers or the industry. It adjusts for the company’s own characteristics rather than assuming all businesses deserve similar multiples. Compared with the current P/E of 56.67x, the Fair Ratio of 18.57x indicates that the shares are trading on a materially richer earnings multiple than this model implies.

Result: OVERVALUED

P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 19 top founder-led companies.

Upgrade Your Decision Making: Choose your Amneal Pharmaceuticals Narrative

Earlier it was mentioned that there is an even better way to think about valuation. Simply Wall St uses Narratives, where you choose a story for Amneal Pharmaceuticals, link that story to a set of revenue, earnings and margin assumptions, and the platform turns it into a Fair Value that you can compare with the current price. This Fair Value updates automatically as news or earnings are released, and can be lined up alongside other views such as a cautious analyst Narrative with a US$15.00 fair value and a more optimistic one at US$18.00. All of these are accessible on the Community page so you can quickly see how different perspectives translate into different numbers and decide what feels reasonable for you.

Do you think there's more to the story for Amneal Pharmaceuticals? Head over to our Community to see what others are saying!

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.